Tesamorelin: GHRH Analog, Visceral Fat Literature, GH Map

People type tesamorelin when they want a GHRH analog with a visceral-fat file.

That is a real lane. It is not the whole GH map.

Tesamorelin is a growth hormone-releasing hormone (GHRH) analog. The labeled drug is Egrifta: FDA-approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. That indication is why the word shows up next to “belly fat” on forums. A research-catalog tesamorelin vial is not Egrifta. Same family conversation. Different manufacturing, regulation, and label.

This page teaches the molecule and places it on the GH map next to sermorelin, CJC-1295 no DAC / ipamorelin, and the class hub on peptides for muscle growth. If a pituitary lecture is not day one, start on Start Here.

This is education. It is not medical advice. It is not a reason to skip a clinician. It is not a “buy this to treat” pitch.

What is tesamorelin?

Tesamorelin is a synthetic GHRH analog. It binds the GHRH receptor on pituitary somatotrophs and asks for a GH pulse when the gland can still answer. You do not get a weekly depot of GH sitting in the blood. You get an axis conversation.

Egrifta (tesamorelin) is FDA-approved for one labeled job: reduce excess abdominal fat in adults with HIV-associated lipodystrophy. That is the drug file people are borrowing when they say “tesamorelin burns visceral fat.” The labeled population, the labeled endpoint, and the labeled product are not a research cake with the same sequence name. Keep those lanes.

Why does the visceral-fat literature matter for education? Because visceral adipose tissue is not the same conversation as “get jacked.” GH secretagogues as a class show up in muscle and recovery talk. Tesamorelin shows up in a fat-distribution talk with a real label behind it. Those can both be true without turning a catalog SKU into a treatment claim.

Half-life and pulse shape still matter. Tesamorelin is still a GHRH-door story. It is not HGH. It is not a steroid. It is not sermorelin with a cooler brand. It is not CJC-1295 no DAC with a fat sticker slapped on. Name the lock. Then decide if this is even the job you meant.

How tesamorelin differs from sermorelin, CJC no DAC, and ipamorelin

You do not need a PhD. You need three keys and one gland.

Lane	What it actually is	What the evidence is	What it is not
Tesamorelin	GHRH analog. Visceral-fat / abdominal-fat literature. The Egrifta-era name.	Egrifta is FDA-approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. A research vial inherits neither the label nor the indication.	Not HGH. Not the only GH answer. Not a catalog shortcut around a labeled drug. Not a muscle-growth crown.
Sermorelin	GHRH 1-29. Short-acting GHRH analog. The beginner search term.	Geref-era diagnostic and pediatric GH-deficiency file. Pulse, not depot. Full map on sermorelin.	Not tesamorelin. Not CJC-1295. Not the analog many experienced users put first.
CJC-1295 no DAC	Mod GRF 1-29. Tetrasubstituted GHRH 1-29. Same door as sermorelin. Harder to degrade. Still a pulse.	Same GHRH-receptor conversation, with DPP-IV resistance. DAC is a different object. Stack page: CJC-1295 and ipamorelin.	Not “tesamorelin that builds muscle.” Not CJC with DAC. Not a steroid.
Ipamorelin	Selective GHS-R agonist. Ghrelin-receptor door. The other key on the same somatotroph.	Raun et al., European Journal of Endocrinology 1998: GH release without the ACTH / cortisol bump they saw with GHRP-6. PubMed.	Not GHRH. Not a visceral-fat drug label. Not “tesamorelin with a cooler name.”

Same family does not mean same job. Tesamorelin and sermorelin both talk to GHRH receptors. The educational difference is the labeled use case and the research people cite next to the name. CJC-1295 no DAC is the pulsatile GHRH analog many people actually run when the job is a GH pulse stack. Ipamorelin is the other door. Put them together and you get the stack page, not a fourth name for tesamorelin.

DAC versus no DAC still wastes money. CJC-1295 with DAC binds albumin and lasts days. That is not tesamorelin. It is not “longer sermorelin.” Keep the pharmacokinetic objects separate.

Who researches it, and what the map is

Researchers and clinicians studying HIV-associated lipodystrophy are the people who put tesamorelin on the map as a labeled drug. That is why visceral fat shows up in every caption. It is also why beginners mash “tesamorelin” into a general fat-loss protocol and skip the label.

Here is the map I want a beginner to hold.

1. Name the door. GHRH or GHRP (GHS-R). Tesamorelin is GHRH. Ipamorelin is GHS-R. Sermorelin and CJC no DAC are GHRH.

2. Name the job. Visceral / abdominal fat literature with a labeled drug in the rear-view is a different conversation from a pulsatile GH stack aimed at recovery and body composition in the gym sense. Do not flatten them.

3. Name the bottle. Egrifta is a drug. A lyophilized research vial with the same sequence name is a research-catalog product. Manufacturing, purity claims, indication, and what you can cite are not interchangeable.

4. Do not crown one analog. Tesamorelin is not the answer to every GH question. Sermorelin won search volume. CJC no DAC / ipamorelin is the stack page for the pulse pair. Tesamorelin is the visceral-fat GHRH lane. Read all three URLs if you are shopping the class. Start on the hub if you still need the two-door lecture: peptides for muscle growth.

Personal preference is not a protocol and not a crown. Preferring one GHRH analog over another for yourself does not make the public page a hustle. The public page teaches the map.

Reconstitution (high level)

If a lyophilized cake is even on the table, learn the math before you invent a protocol. Bacteriostatic water, U-100 syringe ticks, and not wasting ten percent of the vial live on how to reconstitute peptides.

I am not dumping a units-and-days tesamorelin protocol next to that math on a public ranking page. Dose, timing, and duration stay in Pro on purpose. Public page is the map and the reconstitution pointer.

A clinician belongs in the loop for anything that sounds like a drug, because some of these molecules are drugs in another bottle. This page is not a substitute for that visit.

Labs for Tesamorelin

Education first. You already got the map. This block is the labs that list tesamorelin with tracked links I will put my name on. Research-use catalog pages. Not a treatment claim. Not “buy this to treat visceral fat.”

Limitless does not currently list a dedicated tesamorelin product page, so there is no Limitless tesamorelin card here. Paramount, Peptira, and S1 do list it. BioLongevity is linked at shop home when a dedicated product page is not listed here.

Tesamorelin — labs that list it.

BioLongevity home · LEE15

Match the product to the job. Do not collect bottles. Do not use a research catalog as a back door to a labeled drug indication.

Frequently asked questions about tesamorelin

Is tesamorelin the best GH peptide?

No. Tesamorelin is a GHRH analog with a visceral-fat drug file. It is one lane on the GH map. CJC-1295 no DAC and ipamorelin are the pulse stack. Sermorelin is the search term beginners land on. Crowning one analog because a forum caption said “belly fat” is how you skip the map.

Is tesamorelin the same as sermorelin?

No. Both are GHRH-door analogs. Sermorelin is GHRH 1-29 with a Geref-era history. Tesamorelin is a distinct GHRH analog with an Egrifta label for excess abdominal fat in HIV-associated lipodystrophy. Same door family. Different molecule, different labeled job, different page.

Is tesamorelin FDA-approved?

Egrifta (tesamorelin) is FDA-approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. A research-catalog tesamorelin vial is not that labeled drug. It is not an FDA-approved treatment for general weight loss, muscle growth, or aging just because the sequence name matches.

Should I run tesamorelin instead of CJC / ipamorelin?

That is a job question, not a brand question. If you want the pulsatile two-door stack, read CJC-1295 and ipamorelin. If you want the visceral-fat GHRH literature, stay on this page and keep the Egrifta lane honest. If you typed a search term you do not understand yet, read sermorelin and the muscle-growth hub first.

Can I just follow a forum tesamorelin protocol?

You can do a lot of unwise things. I would not. Name the door. Name whether you are talking about Egrifta or a research vial. Name whether the job is visceral fat literature or a GH pulse stack. Protocol depth lives in Pro on purpose. This public page is the map, not the marching orders.

The bottom line

Tesamorelin is a GHRH analog. Egrifta is the FDA-approved drug for excess abdominal fat in adults with HIV-associated lipodystrophy. A research vial is not that drug.

It is not HGH. It is not the only GH answer. Sermorelin, CJC-1295 no DAC, and ipamorelin still own their lanes. The class map lives on the muscle-growth hub. This URL exists because people type the word and deserve the map, not a crown.

Keep the lanes. Read the papers. Do not buy a GHRH cake because a caption said visceral fat.

Read next: ipamorelin and the CJC stack for pulsatile GH talk, sermorelin if that is the word you typed first, and peptides for muscle growth for the class map.

I built Peptides & Pump so you can get this without a guru tax. If you want the protocol library, member discussions, and a place to think out loud before you spend money, that is Pro. If you are not ready to pay, use the free Knowledge Base first.

---

Supplier footnote: Research suppliers I mention when people ask about tesamorelin: Paramount, Peptira (code LEE), and S1 Research (code LEE10). BioLongevity home: LEE15. Limitless had no live tesamorelin product page at publish time. Match the product to the job. Do not collect bottles.

Disclaimer. This article is for educational and research purposes only. It is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Tesamorelin (Egrifta) is FDA-approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy; a research-catalog tesamorelin vial is not Egrifta. Sermorelin acetate (Geref) was an FDA-approved GHRH 1-29 product that was later discontinued; a research-catalog vial is not that labeled drug. CJC-1295 (with or without DAC) and ipamorelin are not FDA-approved for muscle growth, fat loss, or for any indication discussed on this page. Individual results vary. Always consult a qualified healthcare provider before starting any peptide, drug, supplement, or protocol, especially if you have a medical condition or take prescription medication. Peptides & Pump does not sell peptides.

Affiliate disclosure. Some links on this page are affiliate links. If you buy through them, I may earn a commission at no extra cost to you. Codes LEE15, LEE20, LEE10, and LEE are the ones I actually use where a coupon fires. Paramount’s printed code is LEE10. That commission is how I keep publishing free education. I only link suppliers I am willing to put my name on.